entertainment -WSS

entertainment

author：hotspot 2025-09-28 00:51:10 - browse：31

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Device maker Teleflex to acquire urology company for $600M

Wikipedia

entertainment

WSS

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In age of alternative facts, a scholarly course on calling out crap

23andMe had bad news about my health. I wish a person had delivered it

DIEP, the 'gold standard' of breast reconstruction, is under threat

The battle over 'scope creep' and who gets to be called 'doctor'

Anesthesiologist group: stop taking Ozempic before surgery

entertainment

entertainment

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

How to save PrEP access — and even expand it

Jerome Adams on the need for new antivirals for Covid

Jerome Adams on the need for new antivirals for Covid

BioMarin wins approval for gene therapy to treat hemophilia A

Supreme Court strikes down use of affirmative action

Supreme Court strikes down use of affirmative action

Supreme Court strikes down use of affirmative action

Wildfire smoke exposes gaps in outdoor worker protections

Medical leaders decry Supreme Court decision on affirmative action

leisure time

Rise in cancer among younger people worries and puzzles doctors

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC Director Mandy Cohen on transparency, trust, and health

Peter Hotez and the public health issue of online harassment

Biogen says it will cut costs by $700 million, slash 1,000 jobs

CDC Director Mandy Cohen on transparency, trust, and health

Wikipedia

entertainment

explore

explore